Lim Yu Jin, Song Changhoon, Kim Jae-Sung
Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Department of Radiation Oncology, Kyung Hee University Medical Center, Seoul, Republic of Korea.
Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Lung Cancer. 2017 Jun;108:161-167. doi: 10.1016/j.lungcan.2017.03.020. Epub 2017 Mar 31.
Thymic carcinoma is a rare and aggressive malignancy with poor prognosis. Although postoperative radiotherapy (PORT) is used for obtaining better locoregional tumor control, its association with survival has not been established. This study evaluated the prognostic impact of PORT in thymic carcinoma.
We identified patients diagnosed with thymic carcinoma between 2004 and 2013 using the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching with Kaplan-Meier and Cox-regression analyses were used to assess prognosis.
In the unmatched population (n=312), 184 (59%) patients underwent PORT. The 5-year overall survival rates were better with receipt of PORT, both before and after matching (P=0.012 and 0.007, respectively). After adjusting for related covariates (n=256), age ≥63 years (P=0.023), Masaoka stage III (P=0.028) and IV (P<0.001), debulking surgery (P=0.021), and no receipt of PORT (P=0.013) were independently poor prognostic factors. In subgroup analyses, favorable survival impacts of PORT were observed for Masaoka stage III tumors (hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.15-0.66), tumors sized >6.0cm (HR 0.48, 95% CI 0.26-0.89), node-negative status (HR 0.58, 95% CI 0.33-1.00), and surgical extent of local excision or partial removal (HR 0.44, 95% CI 0.22-0.86).
On SEER analysis, survival benefits of PORT in thymic carcinoma were demonstrated. With strong prognostic associations of Masaoka stage and types of surgery, PORT should be considered for non-metastatic locally advanced tumors with limited surgical resection.
胸腺癌是一种罕见的侵袭性恶性肿瘤,预后较差。虽然术后放疗(PORT)用于更好地实现局部区域肿瘤控制,但其与生存率的关联尚未明确。本研究评估了PORT对胸腺癌的预后影响。
我们使用监测、流行病学和最终结果(SEER)数据库,确定了2004年至2013年间被诊断为胸腺癌的患者。采用倾向评分匹配以及Kaplan-Meier和Cox回归分析来评估预后。
在未匹配人群(n = 312)中,184例(59%)患者接受了PORT。匹配前后,接受PORT的患者5年总生存率均更好(分别为P = 0.012和0.007)。在对相关协变量进行调整后(n = 256),年龄≥63岁(P = 0.023)、Masaoka分期III期(P = 0.028)和IV期(P < 0.001)、肿瘤减瘤手术(P = 0.021)以及未接受PORT(P = 0.013)是独立的不良预后因素。在亚组分析中,对于Masaoka分期III期肿瘤(风险比[HR] 0.31,95%置信区间[CI] 0.15 - 0.66)、肿瘤大小>6.0cm(HR 0.48,95% CI 0.26 - 0.89)、淋巴结阴性状态(HR 0.58,95% CI 0.33 - 1.00)以及局部切除或部分切除的手术范围(HR 0.44,95% CI 0.22 - 0.86),观察到PORT对生存有有利影响。
基于SEER分析,证实了PORT对胸腺癌患者生存有益。鉴于Masaoka分期和手术类型与预后密切相关,对于手术切除有限的非转移性局部晚期肿瘤,应考虑PORT。